WO1984002846A1 - Onguent enzymatique - Google Patents

Onguent enzymatique Download PDF

Info

Publication number
WO1984002846A1
WO1984002846A1 PCT/US1984/000079 US8400079W WO8402846A1 WO 1984002846 A1 WO1984002846 A1 WO 1984002846A1 US 8400079 W US8400079 W US 8400079W WO 8402846 A1 WO8402846 A1 WO 8402846A1
Authority
WO
WIPO (PCT)
Prior art keywords
ointment
emollient
skin
wound
penetrating
Prior art date
Application number
PCT/US1984/000079
Other languages
English (en)
Inventor
Gerald L Bilton
Original Assignee
Advanced Drug Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Drug Tech filed Critical Advanced Drug Tech
Publication of WO1984002846A1 publication Critical patent/WO1984002846A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/886Aloeaceae (Aloe family), e.g. aloe vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166Streptokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4826Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator

Definitions

  • prostaglandins i.e. PGE
  • thromboxanes are thought to be synthesized at the trauma site and are believed to be important mediators of the vascular adjustments to be made in the inflammatory response of the body. See, Robbins & Angell, Basic Pathology 38 (2nd ed. 1976).
  • PGE prostaglandin
  • thromboxanes are thought to be synthesized at the trauma site and are believed to be important mediators of the vascular adjustments to be made in the inflammatory response of the body. See, Robbins & Angell, Basic Pathology 38 (2nd ed. 1976).
  • PGE Proliferon filtration
  • thromboxanes are thought to be synthesized at the trauma site and are believed to be important mediators of the vascular adjustments to be made in the inflammatory response of the body. See, Robbins & Angell, Basic Pathology 38 (2nd ed. 1976).
  • clotting factors such as fibrin and thrombin.
  • enzyme blocking factors which prevent fibrin dis
  • necrotic debris which is primarily protein in nature
  • any entrapped bacteria and viruses which are primarily composed of protein and lipids.
  • the accumulation of these substances may be substantial if there is a significant loss of tissue. When this situation occurs, the system is overwhelmed thereby retarding tissue repair.
  • Plasma proteins such as plasminogen and fibrinolysin and the hepatic anticoagulent heparin are usually able to control inflammation during normal homeostasis.
  • Plasma proteins such as plasminogen and fibrinolysin and the hepatic anticoagulent heparin are usually able to control inflammation during normal homeostasis.
  • additional aid is needed by the body to control and alleviate the symptoms of inflammation, since restoration of the damaged tissue cannot be initiated until inflammation is reduced.
  • neutrophils and macrophages contain an abundance of lysosomes containing proteolytic enzymes which are capable of digesting protein matter and bacteria.
  • lysosomes of macrophages are known to contain large quantities of lipases, which are capable of digesting the thick lipid membranes of certain bacteria. See Guyton, Textbook of Medical Physiology 70 (5th ed. 1976).
  • compositions of the present invention are ointments comprising a carrier mixture of penetrating and nonpenetrating emollient oils and a polyhydric alcohol emollient; the proteolytic and other enzymes papain, bromelain, trypsin, chymotrypsin, pancreatin, lipase and amylase; aloe extract; and an organic astringent agent.
  • the carrier mixture, enzymes, aloe extract and the organic astringent agent function synergistically so as to provide an effective wound-healing topical ointment.
  • compositions of the present invention are formulated so as to deliver wound-healing amounts of proteolytic enzymes to the scarred or otherwise traumatized site, in conjunction with reparative quantities of an aloe extract, an organic astringent agent, lipase, amylase, and carrier emollient oils.
  • wound-healing as used herein is intended to refer to the process of tissue repair and to the reduction of symptoms of inflammation present due to the body's response to the cellular disruption of skinsurface mammalian tissue which is either traumatic, as in the case of a burn or cut, or on the other hand, representative of a degenerative process, such as an ulcer.
  • compositions of the present invention include a plurality of proteolytic enzymes, which generally function to hydrolyze or to lyse proteins into their component amino acids, thereby providing these essential amino acids in nutritionally adequate amounts.
  • Fibrolytic, proteolytic enzymes possess the added capacity to lyse or digest fibrin clots at wound sites. This action tends to restore the free flow of blood through the circulatory system thereby accelerating the healing process at wound sites and minimizing the development of scar tissue.
  • compositions of the invention will comprise one or more of the proteolytic enzymes streptokinase, urokinase, trypsin, chymotrypsin, papain, bromelain and pancreatin. In a preferred embodiment, all of these enzymes except streptokinase and urokinase are contained in the composition.
  • Trypsin and chymotrypsin have been demonstrated to be successful in the dissolution of the clotting factor fibrin, necrotic tissue and proteinaceous exudates. When applied topically to post-thrombotic leg ulcers, they have shown remarkable success in accelerating the healing process. See, Gordon, The Use of Topical Proteolytic Enzymes in the Treatment of Post-thrombotic Leg Ulcers, Brit. J. Clin. Prac. , 29, 143 (1975). Moreover, trypsin and chymotrypsin are thought to have a favorable influence on the inflammatory process in thromophlebitis. It is expected that streptokinase and urokinase would exhibit similar actions when applied topically in an active form, and may be used in addition to, or as replacements for, the trypsins.
  • trypsin and chymotrypsin are often used in combination for the prevention and treatment of inflammation from injury, each may be used in the formulation of the present invention without the other.
  • trypsin will make up about .025-2.5% by weight and chymotrypsin about .001-1% by weight of the compositions of the present invention and most preferably, about .05-1% and .002-.1%, respectively.
  • Papain has been reported to achieve excellent results in promoting the healing of wounds. See, Hwang & Ivy, A Review of the Literature on the Potential Therapeutic Significance of Papain, Annals N.Y. Acad. Science, 54, 161 (1951-52). Indeed, papain has demonstrated clinical efficacy as a local agent to debride or solubilize collections of proteinaceous materials in an antiinflammatory role. See, Emele et al., The AnalgesicAnti-Inflammatory activity of Papain, Arch. Int.
  • Papain is considered to be clinically efficacious in a topical application in removing clotted blood, purulent exudate and necrotic tissue from skin-surface wounds and ulcers.
  • papain will make up about .05-5% by weight of the compositions according to the invention and most preferably, about .1-2%.
  • bromelain acts to selectively inhibit the biosynthesis of proinflammatory prostaglandins, such as the platelet-aggregating thromboxanes.
  • proinflammatory prostaglandins such as the platelet-aggregating thromboxanes.
  • endogenous proteases such as circulating plasmin, trypsin, chymotrypsin, and lipases are inhibited by trauma or exposure to excessive stress.
  • Bromelain also acts on fibrinogen and fibrin to yield products similar to those formed by plasmin and which stimulate the biosynthesis of anti-inflamatory prostaglandins such as PGI 2 .
  • bromelain will make up about .05-5% by weight of the total enzyme component of the composition according to the invention and most preferably, about .1-2%.
  • compositions of the invention will also preferably incorporate an amount of pancreatin, or of the individual primary enzymes incorporated therein, or of mixtures of the individual enzymes with pancreatin.
  • Pancreatin primarily contains amylase, protease and lipase; digestive enzymes which act to break down dietary starch, protein and fat, respectively. Since pancreatic deficiency or overload is implicated in many situations involving wounds, it is believed that a supplemental amount of pancreatin is a beneficial adjunct to the administration of the fibrinolytic and anti-inflammatory enzymes. Pancreatin aids in the restoration of normal digestive processes, including the proper metabolism of fats, which is necessary for the achievement of effective plasma levels of anticlotting and antiinflammatory prostaglandins.
  • Pancreatin and/or its component enzymes preferably comprise up to about .1-10% by weight of the compositions of the present invention, most preferably about .2-2%.
  • the compositions of the present invention will also preferably include topically wound-cleansing amounts of pancreatic digestive enzymes such as lipases and/or amylases, which are thought to effect the fats and carbohydrates contained in the structure of bacteria and viruses. For instance, many types of viruses possess an outer cell envelope composed of protein, lipid and carbohydrate constituents.
  • Amylase and/or lipase in conjunction with the proteolytic enzymes of the present invention, are thought to act synergistically to degrade the cell envelope and protein and lipid components of the virus particle so as to inactivate the pathenogicity of viruses contained in or entering the wound.
  • compositions of the invention are thought to act on the cell wall and membrane of the bacterial cell leading to the lysing of the microorganism with a consequent loss of virulence. In this manner, wound-healing is aided by the control of infectious microorganisms.
  • the pancreatic digestive enzymes such as lipase and amylase will each make up about .01-5% of the compositions of the present invention and most preferably, about .05-1%.
  • compositions according to the invention may also include an aloe extract and an organic astringent agent.
  • aloe extract which is preferably incorporated as an aloe concentrate, e.g. aloe vera or aloe perryi concentrate, is thought to promote healing and has been applied as a soothing cream to skin-surface wounds, burns and scar tissue.
  • the aloe extract contains enzymes which promote the removal of dead skin while stimulating the normal growth of living tissue.
  • aloe extract refers to the inspissated juice of the aloe plant as well as to its dried concentrates which contain aloe-emodin, aloin or other active anthraquinone principles.
  • the preferable organic astringent agent is witch hazel, a herb substance which has demonstrated effectiveness as an astringent for the treatment of itching, skin irritations and burns. This compound acts to inhibit the pathological transcapillary movement of plasma protein thereby reducing inflammation, edema and exudation.
  • Witch hazel has been used in an antiseptic capacity for the healing of wounds and for cleansing the skin surface.
  • compositions of the present invention may also include one or more of a mixture of carrier emollients of a penetrating emollient oil, a non-penetrating emollient oil and a polyhydric alcohol emollient.
  • the penetrating emollient oil will be ethoxylated lanolin.
  • lanolin is known to be effective as a moisturizer and lubricant. The substance penetrates into the skin surface quickly and is quite beneficial when applied to skin-surface wounds since it acts to prevent a dressing from sticking to the wound. This effective penetrator also acts to replenish valuable lipids in the wound area.
  • Other characteristics of lanolin are disclosed in U.S. Patent No. 2,478,820, the disclosure of which is incorporated herein by reference. Useful compounds of this type are formed by the condensation of about 10-80 moles of ethylene oxide per mole of lanolin or by the linking of sorbitol and lanolin with a polyoxyethylene chain containing 10-80 moles of ethylene oxide.
  • Atlas ® G-1790 (20 moles of ethylene oxide/mole of lanolin)
  • Atlas ® G-1441 40 moles of ethylene oxide linking sorbitol and lanolin
  • Atlas ® G-1471 75 moles of ethylene oxide linking sorbitol and lanolin
  • the preferred non-penetrating emollient oil is petrolatum, which is known to aid in restoring the natural texture of the skin surface.
  • petrolatum is a non-penetrating moisturizer and lubricant for the skin surface and as such, acts to aid in the topical action of the composition of the present invention.
  • the preferred polyhydric alcohol emollient is glycerin. Its main utility is in moisturizing the skin and providing a medium solvent. It is also reported to possess therapeutic uses such as its application to reduce corneal edema. See, Remington's Pharmaceutical Sciences, A. Ossol ed, Mack Pub., Boston, Mass. (16th ed. 1980) at page 1255.
  • the weight percent of the carrier emollients is substantially greater than that of any of the other components of the invention.
  • the carrier emollients comprise about 85-99% of the total weight of the compositions of the present invention and most preferably, about 93-97%.
  • compositions of the present invention may also include one or more antibacterial preservatives, preferably from the C 1 -C 4 lower alkyl benzoates such as methyl and propyl paraben, each with a total weight percent in the compositions of about .025-1.5%, preferably.
  • antibacterial preservatives preferably from the C 1 -C 4 lower alkyl benzoates such as methyl and propyl paraben, each with a total weight percent in the compositions of about .025-1.5%, preferably.
  • the total weight percent of the components of the compositions of the present invention may be varied over a wide range.
  • the weight percent of all of the enzymes in the compositions is preferably about .2- 20% and of just the proteolytic enzymes, about .2-15%.
  • the weight percent of aloe extract preferably ranges from about .05-3% and the weight percent of the organic astringent agent preferably ranges from about .06-3% .
  • the respective weight percents would be as follows: enzymes, .2-20%; aloe extract, 0.02-10%, or preferably .05-3%; organic astringent agent, .025-8%, or preferably .06-3%; petrolatum, 40-80%; ethoxylated lanolin, 5-30%; glycerine 5-30%, and preservatives .05-3%.
  • compositions of the present invention will be formulated such that the total enzyme component will comprise, by weight, papain, about 15-40%; trypsin, about 5-15%; chymotrypsin, about .2-.6%; bromelain, about 10-30%; pancreatin, about 30-50%; lipase, about 2-8%; and amylase, about 2-8%.
  • the total enzyme component will comprise, by weight, papain, about 15-40%; trypsin, about 5-15%; chymotrypsin, about .2-.6%; bromelain, about 10-30%; pancreatin, about 30-50%; lipase, about 2-8%; and amylase, about 2-8%.
  • the wound-healing, reparative quality of the ointment may be effectuated by means of the method according to the present invention.
  • the method comprises the topical administration of an effective amount of the hereinabove discussed compositions to traumatic or degenerative skin-surface wounds.
  • the ointments are typically prepared by first mixing the carrier emollients. A second homogeneous mixture of enzymes and aloe extract is then slowly incorporated into a small amount of the carrier emollient mixture. The resultant paste is then added to the remainder of the carrier emollient mixture while mixing in a mixer. A second homogeneous paste, composed of the organic astringent agent and a small quantity of the carrier emollient mixture is then added to the mixer and mixing of all the components is continued until the composition begins to solidify. At this time, the composition is poured into a tube filling apparatus, pressure is applied and the ointment is tubed.
  • a melt of 15,162 g of petrolatum, 4,364 g of ethoxylated lanolin and 3,509 g of glycerin was prepared in a stainless steel container.
  • Small amounts of a second homogeneous mixture of 252 g of pancreatin, 153 g papain, 113 g of bromelain, 25 g of lipase, 25 g of amylase, 60 g of trypsin, 2.5 g of chymotrypsin and 42 g of aloe vera powder extract were added to small quantities of the melt in a 2 gallon stainless steel container.
  • the resultant paste was added to a larger quantity of the melt while mixing until homogeneous in a "J.H. Day" mixer.
  • a second paste was made of 84 g of witch hazel extract and a small amount of melt.
  • the paste was homogeneous, it was added to the first paste with mixing.
  • the homogeneous mixture began to solidify, it was poured Into a "Colton" tube filling machine and one ounce tubes were filled under 30 lbs. pressure.
  • the ointment of this invention has been used in the treatment of superficial wounds and bruises and has been reported as effective for such applications in providing symptomatic relief.
  • the recommended mode of application is to apply a thin layer of the ointment to the afflicted area and optionally cover with a sterile gauze dressing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Onguent topique pour des blessures de la surface de la peau contenant des quantités thérapeutiques de papaïne, de bromelaïne, de trypsine, de chromotrypsine, de pancréatine, de lipase, d'amylase, d'extraits d'aloès, ainsi qu'un agent astringent organique formulé dans un mélange porteur d'huiles émollientes pénétrantes et non pénétrantes et d'un émollient d'alcool polyhydrique. L'onguent réduit l'inflammation à l'endroit des blessures de la surface de la peau et provoque l'accroissement des activités anti-inflammatoires normales du corps.
PCT/US1984/000079 1983-01-21 1984-01-18 Onguent enzymatique WO1984002846A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46002383A 1983-01-21 1983-01-21

Publications (1)

Publication Number Publication Date
WO1984002846A1 true WO1984002846A1 (fr) 1984-08-02

Family

ID=23827108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1984/000079 WO1984002846A1 (fr) 1983-01-21 1984-01-18 Onguent enzymatique

Country Status (3)

Country Link
EP (1) EP0133438A1 (fr)
CA (1) CA1222453A (fr)
WO (1) WO1984002846A1 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358500A1 (fr) * 1988-09-08 1990-03-14 The Public Health Laboratory Service Board Méthode et composition en vue du traitement et de la prévention des infections virales
FR2646605A1 (fr) * 1989-05-08 1990-11-09 Shigemi Fujisaki Activateur de neurones endommages, servant a la prevention et au traitement de maladies
DE4130221A1 (de) * 1991-09-11 1993-03-18 Mucos Pharma Gmbh Verwendung von proteolytischen enzymen zur herstellung eines medikaments zur behandlung einer krankheit, an deren entstehung proteine mit einer c(pfeil abwaerts)h(pfeil abwaerts)2-domaene beteiligt sind
DE4305460A1 (de) * 1993-02-23 1994-08-25 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme umfassende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
US5439935A (en) * 1992-04-02 1995-08-08 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
US5543149A (en) * 1995-03-01 1996-08-06 Rubin; Stan M. Treatment for insect bites
US5545402A (en) * 1993-09-15 1996-08-13 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
US5554366A (en) * 1992-04-02 1996-09-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
US5665366A (en) * 1993-09-15 1997-09-09 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
GR1003080B (el) * 1997-11-21 1999-02-25 Συντηρηση ενζυμων σε κοιλο πωμα φιαλιδιων για χρηση τους σε καλλυντικα σκευασματα
EP1051142A1 (fr) * 1997-10-16 2000-11-15 Deguang Zhu Nouvelle composition cosmetique ou pharmaceutique puissante
WO2003066088A2 (fr) * 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Criblage de proteases et nouvelle utilisation de proteases
WO2006046025A1 (fr) * 2004-10-25 2006-05-04 Coventry University Compositions pour rehausser les levres
WO2013116732A1 (fr) * 2012-02-02 2013-08-08 Curelon Llc Compositions enzymatiques et leur utilisation pour la cicatrisation
GB2480772B (en) * 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
GB2480773B (en) * 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
WO2016057788A1 (fr) 2014-10-10 2016-04-14 Rochal Industries, Llc Compositions et kits pour le débridement enzymatique et leurs procédés d'utilisation
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US10238719B2 (en) 2014-10-10 2019-03-26 Rochal Industries, Llc Compositions and kits for enzymatic debridement and methods of using the same
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10688159B2 (en) 2014-10-10 2020-06-23 Rochal Industries, Llc Compositions and kits for treating pruritus and methods of using the same
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106860860A (zh) * 2017-03-03 2017-06-20 钱安坤 多酶片的新应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917433A (en) * 1956-04-02 1959-12-15 Rystan Company Stable aqueous papain topical compositions
US3878197A (en) * 1972-12-13 1975-04-15 Ray H Maret Process for preparing extracts of aloe vera
US3892853A (en) * 1967-05-22 1975-07-01 Aloe 99 & 0 Inc Stabilized aloe vera gel and preparation of same
US3932618A (en) * 1971-04-14 1976-01-13 Otsuka Kagaku Yakuhin Kabushiki Kaisha Anti-inflammatory compositions
US4361551A (en) * 1979-11-05 1982-11-30 Riker Laboratories, Inc. Method of enzymatic debridement

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917433A (en) * 1956-04-02 1959-12-15 Rystan Company Stable aqueous papain topical compositions
US3892853A (en) * 1967-05-22 1975-07-01 Aloe 99 & 0 Inc Stabilized aloe vera gel and preparation of same
US3932618A (en) * 1971-04-14 1976-01-13 Otsuka Kagaku Yakuhin Kabushiki Kaisha Anti-inflammatory compositions
US3878197A (en) * 1972-12-13 1975-04-15 Ray H Maret Process for preparing extracts of aloe vera
US4361551A (en) * 1979-11-05 1982-11-30 Riker Laboratories, Inc. Method of enzymatic debridement

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 72, published 1970, Abstract No. 136409j *
Dispensatory of U.S.A. (OSOL & FARRAR) published 1955, pages 612, 633, 1024 and 1025 *

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358500A1 (fr) * 1988-09-08 1990-03-14 The Public Health Laboratory Service Board Méthode et composition en vue du traitement et de la prévention des infections virales
WO1990002562A1 (fr) * 1988-09-08 1990-03-22 Public Health Laboratory Service Board Procede et composition de traitement et de prevention d'infections virales
FR2646605A1 (fr) * 1989-05-08 1990-11-09 Shigemi Fujisaki Activateur de neurones endommages, servant a la prevention et au traitement de maladies
DE3941324A1 (de) * 1989-05-08 1990-11-15 Shigemi Fujisaki Aktivator fuer verletzte neurozyten zur verhuetung und behandlung von krankheiten
DE3941324C2 (fr) * 1989-05-08 1992-06-25 Fujisaki, Shigemi, Nishinomiya, Hyogo, Jp
DE3943649C2 (fr) * 1989-05-08 1992-10-29 Fujisaki, Shigemi, Nishinomiya, Hyogo, Jp
DE4130221A1 (de) * 1991-09-11 1993-03-18 Mucos Pharma Gmbh Verwendung von proteolytischen enzymen zur herstellung eines medikaments zur behandlung einer krankheit, an deren entstehung proteine mit einer c(pfeil abwaerts)h(pfeil abwaerts)2-domaene beteiligt sind
US5439935A (en) * 1992-04-02 1995-08-08 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
US5554366A (en) * 1992-04-02 1996-09-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
DE4305460A1 (de) * 1993-02-23 1994-08-25 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme umfassende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
US5545402A (en) * 1993-09-15 1996-08-13 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
US5665366A (en) * 1993-09-15 1997-09-09 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
US5543149A (en) * 1995-03-01 1996-08-06 Rubin; Stan M. Treatment for insect bites
WO1996026739A1 (fr) * 1995-03-01 1996-09-06 Rubin Stan M Utilisation d'enzymes proteolytiques dans le traitement des piqures d'insectes
EP1051142A1 (fr) * 1997-10-16 2000-11-15 Deguang Zhu Nouvelle composition cosmetique ou pharmaceutique puissante
EP1051142A4 (fr) * 1997-10-16 2002-01-30 Deguang Zhu Nouvelle composition cosmetique ou pharmaceutique puissante
WO1999026856A1 (fr) * 1997-11-21 1999-06-03 Katsikas, Marios Recipient de melange a compartiment double pour melanges renfermant des enzymes utiles pour traiter l'acne
GR1003080B (el) * 1997-11-21 1999-02-25 Συντηρηση ενζυμων σε κοιλο πωμα φιαλιδιων για χρηση τους σε καλλυντικα σκευασματα
US6627192B1 (en) 1997-11-21 2003-09-30 Spyros Tsakas Use of dual compartment mixing container for enzyme mixtures useful to treat acne
US9624525B2 (en) 1999-12-17 2017-04-18 Curemark, Llc Method for treating pervasive development disorders
US9624526B2 (en) 1999-12-17 2017-04-18 Curemark Llc Method for treating pervasive development disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US10209253B2 (en) 2000-11-16 2019-02-19 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
WO2003066088A2 (fr) * 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Criblage de proteases et nouvelle utilisation de proteases
WO2003066088A3 (fr) * 2002-02-06 2004-04-01 Trommsdorff Arzneimittel Criblage de proteases et nouvelle utilisation de proteases
WO2006046025A1 (fr) * 2004-10-25 2006-05-04 Coventry University Compositions pour rehausser les levres
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US10350229B2 (en) 2005-08-30 2019-07-16 Curemark, Llc Use of lactulose in the treatment of autism
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9925250B2 (en) 2008-03-13 2018-03-27 Curemark, Llc Method of treating proteinuria in pregnancy
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US9687534B2 (en) 2008-04-18 2017-06-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US10272141B2 (en) 2008-04-18 2019-04-30 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US10588948B2 (en) 2008-06-26 2020-03-17 Curemark, Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US9687535B2 (en) 2008-10-03 2017-06-27 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US10413601B2 (en) 2008-10-03 2019-09-17 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
GB2480773B (en) * 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
GB2480772B (en) * 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US10736946B2 (en) 2009-01-06 2020-08-11 Galenagen, Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9895427B2 (en) 2009-01-06 2018-02-20 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US10098844B2 (en) 2009-04-13 2018-10-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9931302B2 (en) 2009-04-13 2018-04-03 Curemark , LLC Enzyme delivery systems and methods of preparation and use
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10716835B2 (en) 2009-10-21 2020-07-21 Curemark, Llc Methods and compositions for the prevention and treatment of influenza
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US10279016B2 (en) 2011-04-21 2019-05-07 Curemark, Llc Method of treatment of schizophreniform disorder
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
CN107261126A (zh) * 2012-02-02 2017-10-20 加尔纳根有限责任公司 酶组合物及其用于创伤愈合的用途
CN104220088A (zh) * 2012-02-02 2014-12-17 柯尔朗恩有限责任公司 酶组合物及其用于创伤愈合的用途
WO2013116732A1 (fr) * 2012-02-02 2013-08-08 Curelon Llc Compositions enzymatiques et leur utilisation pour la cicatrisation
US20220096611A1 (en) * 2012-02-02 2022-03-31 Galenagen, Llc Enzyme compositions and use thereof for wound healing
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US10688159B2 (en) 2014-10-10 2020-06-23 Rochal Industries, Llc Compositions and kits for treating pruritus and methods of using the same
US10238719B2 (en) 2014-10-10 2019-03-26 Rochal Industries, Llc Compositions and kits for enzymatic debridement and methods of using the same
WO2016057788A1 (fr) 2014-10-10 2016-04-14 Rochal Industries, Llc Compositions et kits pour le débridement enzymatique et leurs procédés d'utilisation
US9592280B2 (en) 2014-10-10 2017-03-14 Rochal Industries Llc Compositions and kits for enzymatic debridement and methods of using the same
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Also Published As

Publication number Publication date
EP0133438A1 (fr) 1985-02-27
CA1222453A (fr) 1987-06-02

Similar Documents

Publication Publication Date Title
WO1984002846A1 (fr) Onguent enzymatique
DE60014659T2 (de) Pharmazeutische- und kosmetischezusammensetzungen enthaldend serinproteasen aus kabeljau und deren pharmazeutische und kosmetische verwendung
AU778792B2 (en) Composition and method for enhancing wound healing
US10206982B2 (en) Wound debridement compositions containing seaprose and methods of wound treatment using same
US8945636B2 (en) Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care
US20080014169A1 (en) Compositions for Topical Enzymatic Debridement
Margolis et al. Management of chronic venous leg ulcers: a literature-guided approach
US7879798B1 (en) Composition for indolent wound healing and methods of use therefor
US6033664A (en) Use of a preparation comprising a plasminogen activator to improve wound healing
US20150297687A1 (en) Protease compositions for the treatment of damaged tissue
CN114053175B (zh) 一种祛痘产品及其制备方法
EP2570124B1 (fr) Compositions d'oleuropéine pour la cicatrisation de plaies et d'ulcères chez des personnes âgées et/ou diabétiques
Witkowski et al. Debridement of cutaneous ulcers: medical and surgical aspects
Hellgren Cleansing properties of stabilized trypsin and streptokinase-streptodornase in necrotic leg ulcers
US11141458B2 (en) Composition and methods for promoting and treating chronic wound healing
RU2165754C2 (ru) Мазь для лечения гнойновоспалительных заболеваний, ожогов, воспалительных заболеваний суставов, трофических язв и длительно незаживающих ран, способ ее приготовления и способ лечения
CN1072482C (zh) 低分子肝素脂质体喷胶剂及制备工艺
KR102221141B1 (ko) 여드름 피부 개선용 화장료 조성물
EP1982694B1 (fr) Composition anti-'dème
Muhlemann et al. Skin Infections in the Elderly
EP0103955A2 (fr) Traitement du pied d'athlète
WO2006032464A2 (fr) Procede pour traiter des lesions cutanees exsudatives aigues et composition utilisee dans le procede
BG66767B1 (bg) Биологично активен състав

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): JP

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE